Leap Therapeutics is a biopharmaceutical company developing biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. Co.'s primary clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1. Co.'s second clinical stage program is FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface. Co. also has two preclinical antibody programs, FL-302 and FL-501.
|
Free LPTX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (3.75 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |